Introduction
============

Uric acid, the end product of an exogenous pool of purines, which functions as either an antioxidant or a pro-oxidant, has been reported as a predictor of outcomes in multiple diseases.[@b1-tcrm-14-1347]--[@b4-tcrm-14-1347] Related research studies focused mainly on cardiovascular disease and found that uric acid might serve as a biomarker of severity of coronary artery disease in patients with acute coronary syndrome, cardiovascular mortality, 1-year mortality of patients with acute coronary syndromes treated with percutaneous coronary intervention, and might improve the prognostic accuracy of some clinical models.[@b5-tcrm-14-1347]--[@b8-tcrm-14-1347] The prognostic and predictive value of uric acid was also explored in type 2 diabetic patients and patients who had open heart surgery.[@b9-tcrm-14-1347],[@b10-tcrm-14-1347] However, the value of initial serum uric acid on admission in critically ill patients seems limited. Akbar et al reported that elevated uric acid levels in patients with sepsis are associated with an increased risk of acute kidney injury and acute respiratory distress syndrome, but Zhu et al found that there was no correlation between the initial levels of serum uric acid and prognosis of infection in critically ill patients.[@b11-tcrm-14-1347],[@b12-tcrm-14-1347] Meanwhile, it has been reported that no relationship was found between serum uric acid and short-term mortality of critically ill patients.[@b13-tcrm-14-1347],[@b14-tcrm-14-1347] To the best of our knowledge, there is no research to evaluate the association of serum uric acid on intensive care unit (ICU) admission with long-term outcome of critically ill patients. Thus, we performed a retrospective cohort study using a modifiable data mining technique applied to the publicly available Medical Information Mart for Intensive Care III (MIMIC-III) database, aiming to clarify whether there is an association between admission serum uric acid levels and long-term outcome.[@b15-tcrm-14-1347]

Materials and methods
=====================

Study design and data sources
-----------------------------

We conducted a retrospective cohort study using data extracted from the MIMIC-III database, which is a large publicly available database consisting of de-identified health-related data of patients who had stayed in the ICU of Beth Israel Deaconess Medical Center between 2001 and 2012. Access to database has been approved by the institutional review boards of both Beth Israel Deaconess Medical Center and Massachusetts Institute of Technology Affiliates. No informed consent was required on the de-identified patients.

Participants
------------

Adult patients (aged ≥18 years) of first hospital admission and first ICU admission were considered and included, but patients staying at ICU for \<1 day and patients without admission serum uric acid records were excluded. In addition, patients whose death was earlier than ICU admission time and patients whose length of hospital stay was less than length of ICU stays were excluded in order to exclude potential typographical errors and records of organ donor account ([Figure 1](#f1-tcrm-14-1347){ref-type="fig"}).

Variables
---------

We applied Structured Query Language to extract data from the database mainly by using codes from the MIMIC Code Repository.[@b16-tcrm-14-1347],[@b24-tcrm-14-1347] Age, sex, ICU mortality and hospital mortality, length of ICU stay and length of hospital stay, 28-day mortality and 90-day mortality, admission serum uric acid (admission was defined as within 24 hours after ICU admission), Simplified Acute Physiology Score II (SAPS II), the Elixhauser comorbidities, and the Elixhauser Comorbidity Index (State Inpatient Database \[SID\]30) were extracted or calculated.[@b17-tcrm-14-1347]--[@b19-tcrm-14-1347] Missing components for the calculation of SAPS II were treated as normal (usually 0). Because the database has had date of birth of patients who are older than 89 years shifted to exactly 300 years before to obscure their age, we corrected them (age −300+89) before analysis.

Outcome measures
----------------

Ninety-day mortality after ICU admission was chosen as the primary end point, and 28-day mortality, hospital mortality, and ICU mortality were secondary outcomes. ICU mortality was determined only by the first ICU stay.

Propensity score matching (PSM)
-------------------------------

We grouped the study subjects as survivors and non-survivors according to their 90-day survival status after ICU admission. The propensity score for each patient was calculated to estimate their probability of death during the first 90 days after ICU admission by using multivariable logistic regression models given the following covariates: gender, age, SAPS II, Elixhauser Comorbidity Index (SID30), sepsis (based on International Classification of Diseases, Ninth Revision \[ICD-9\] codes), mechanical ventilation on the first day, renal replacement therapy on the first day, congestive heart failure, cardiac arrhythmias, valvular disease, pulmonary circulation disorder, peripheral vascular disorder, hypertension, paralysis, other neurological disease, chronic pulmonary disease, uncomplicated diabetes, complicated diabetes, hypothyroidism, renal failure, liver disease, peptic ulcer, acquired immune deficiency syndrome, lymphoma, metastatic cancer, solid tumor, rheumatoid arthritis, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psychoses, and depression. Matching was performed with the use of a 1:1 matching protocol without replacement (greedy-matching algorithm), with a caliper width equal to 0.05 of the standard deviation of the logit of the propensity score. The overlap of the distribution of the propensity scores across survivors and non-survivors groups is shown in [Figure S1](#SD1-tcrm-14-1347){ref-type="supplementary-material"}.

Statistical analysis
--------------------

For continuous variables, data were expressed as median and interquartile range (IQR) unless otherwise stated. For categorical variables, data were shown as numbers and percentages. Comparison of continuous and categorical variables was performed using Kruskal-Wallis and chi-square (or Fisher's exact) tests, respectively. We used receiver operating characteristic (ROC) curves to evaluate the prognostic predictive value of serum uric acid for 90-day mortality and other outcomes and used the Kaplan--Meier (K-M) method and log-rank tests to compare survival differences among patients of different admission serum uric acid levels. Variables associated with 90-day mortality were evaluated by univariate Cox regression analysis, and those with a *p*-value \<0.1 were considered in multivariable Cox regression model. Considering the expected collinearity between comorbidities and the Elixhauser Comorbidity Index (SID30), we would choose only either one of them to be enrolled into one adjusted model when variables are potentially significant (*p*\<0.1) in univariate analysis. Age was not included in the multivariable regression analysis since it was factored into SAPS II. Multivariable Cox regression model was performed to evaluate the association of serum uric acid on 90-day mortality and 28-day mortality, and multivariable logistic regression model was used to examine the association between hospital mortality and ICU mortality. *p*-values of \<0.05 were considered to indicate statistical significance. Empower(R) ([www.empowerstats.com](www.empowerstats.com); X&Y solutions, Inc., Boston, MA, USA) and R software, version 3.4.3 (<http://www.r-project.org>; R Foundation for Statistical Computing, Vienna, Austria) were used for statistical analyses.

Results
=======

Patient characteristics
-----------------------

A total of 2,123 patients were included ([Figure 1](#f1-tcrm-14-1347){ref-type="fig"}). As shown in [Table 1](#t1-tcrm-14-1347){ref-type="table"}, the median age of the study patients was 64.09 years (IQR 51.39--75.74 years) and 1,219 of the 2,123 cases (57.42%) were male. The median admission serum uric acid was 5.40 mg/dL (IQR 3.80--7.90 mg/dL) with a median SAPS II score of 39 (IQR 30--49). Among them, 239 (11.26%) patients were diagnosed with sepsis based on ICD-9 codes and 1,032 (48.61%) patients required mechanical ventilation on admission. The five most common comorbidities were fluid and electrolyte disorders (38.48%), congestive heart failure (20.35%), deficiency anemia (20.16%), cardiac arrhythmias (20.07%), and coagulopathy (19.31%). The 90-day mortality was 27.23% with 578 non-survivors and 1,545 survivors. The length of ICU stay and hospital stay was 3.79 (IQR 2.01--9.19) and 14.69 (IQR 8.05--26.37) days, respectively. Non-survivors had significantly higher SAPS II (*p*\<0.001). No statistically significant difference was observed in serum uric acid between survivors and non-survivors.

Characteristics of the PSM cohort
---------------------------------

A total of 556 non-survivors were successfully matched with one control. Characteristics of PSM cohort are shown in [Table 2](#t2-tcrm-14-1347){ref-type="table"}. There was no statistically significant difference between survivors and non-survivors in age, gender, SAPS II on admission, Elixhauser Comorbidity Index (SID30), and comorbidities (*p*\>0.05), and no statistically significant difference was found on serum uric acid between survivors and non-survivors.

Survival status of patients with different serum uric acid levels on admission
------------------------------------------------------------------------------

Patients were grouped according to their serum uric acid levels on admission. The K-M survival curves presented in [Figure 2](#f2-tcrm-14-1347){ref-type="fig"} showed that there was no difference in the survival rate among different serum uric acid levels on admission (log-rank test: *p*=0.88) after PSM. The K-M survival curves of 28-day mortality are shown in [Figure S2](#SD2-tcrm-14-1347){ref-type="supplementary-material"}.

ROC curve analysis
------------------

As shown in [Figure 3](#f3-tcrm-14-1347){ref-type="fig"}, the area under the ROC curve (AUC) of admission serum uric acid for discrimination of 90-day survivors and non-survivors was 0.522 (95% confidence interval \[CI\] 0.494--0.550) and 0.511 (95% CI 0.477--0.545) for all patients and PSM cohort, respectively. ROC curve analysis of other outcomes also indicated a poor predictive value of serum uric acid.

Association between serum uric acid levels on admission and ICU outcomes
------------------------------------------------------------------------

Results of univariate Cox regression analysis of all patients and PSM cohort are presented in [Tables S1](#SD3-tcrm-14-1347){ref-type="supplementary-material"} and [S2](#SD4-tcrm-14-1347){ref-type="supplementary-material"}, respectively. As shown in [Table 3](#t3-tcrm-14-1347){ref-type="table"}, multivariable regression analysis of PSM cohort indicated that serum uric acid was not an independent risk factor of 90-day mortality (hazard ratio \[HR\] 1.00, 95% CI 0.98--1.03, *p*=0.6835), 28-day mortality (HR 1.01, 95% CI 0.98--1.04, *p*=0.4894), hospital mortality (odds ratio \[OR\] 1.01, 95% CI 0.97--1.04, *p*=0.6099), and ICU mortality (OR 1.01, 95% CI 0.97--1.05, *p*=0.6934). Results of regression analysis of all patients are also shown in [Table 3](#t3-tcrm-14-1347){ref-type="table"}.

Discussion
==========

For the first time, the present study evaluated the association between serum uric acid on ICU admission and long-term outcome of critically ill patients. Results of the study indicated that serum uric acid on admission cannot predict long-term outcome of critically ill patients.

It is interesting to find no correlation between serum uric acid with clinical outcomes of critically ill patients, since many studies had reported the prognostic predictive value of serum uric acid in many clinical conditions. For example, uric acid was found to be an independent predictor of cardiovascular outcomes and increase prognostic accuracy of Cox models in hypertensives with normal renal function which allowed a risk reclassification according to a recent report of Perticone et al.[@b8-tcrm-14-1347] Given serum uric acid is increased in respiratory disease, especially in the presence of hypoxia and systemic inflammation, many researchers wondered whether it could serve as a biomarker of prognostic predictive value.[@b20-tcrm-14-1347] Nagaya et al reported that serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension.[@b21-tcrm-14-1347] Bartziokas et al found that serum uric acid was associated with increased 30-day mortality and risk for future acute exacerbation of chronic obstructive pulmonary disease.[@b22-tcrm-14-1347] Ergun et al reported that high serum uric acid levels are predictive for not only long-term mortality but also for short-term mortality.[@b23-tcrm-14-1347] However, in terms of critically ill patients, only a few studies were conducted to explore the value of uric acid and most of the conclusions were negative.[@b12-tcrm-14-1347]--[@b14-tcrm-14-1347] Considering that most of the previous studies evaluated only the short-term outcomes with limited sample sizes, we conducted this present study aiming to evaluate the predictive value of serum uric acid for long-term outcome of critically ill patients. In our study, we included over 2,000 patients which made enough adjustment for confounders available and improved statistical power. Meanwhile, we performed PSM to further minimize the potential selection bias. Results of all patients and PSM cohort were consistent and provided a solid conclusion of the association between serum uric acid and 90-day mortality for critically ill patients, although negative. We also examined some short-term outcomes in the study, and the results were consistent with previous studies.

Although the findings in our study were informative, there were several limitations in the present study. First, given the observational nature of our study, it is not possible to adjust all potential confounders. Although we considered many variables known to affect the outcomes, unmeasured confounders may have affected our results. As we know, the reference value of serum uric acid is different between male and female; hence, gender must be considered in the K-M survival curves. In fact, the results were consistent even after grouped by sex (data not shown), but there were still other potential confounders such as renal replacement therapy on the first day, fluid and electrolyte disorders, which made it difficult to take all these confounders into consideration in the K-M curves. And since there were too many specific primary diagnoses for all the patients, we categorized the primary diseases as several comorbidities ([Tables 1](#t1-tcrm-14-1347){ref-type="table"} and [2](#t2-tcrm-14-1347){ref-type="table"}) to make it easier to adjust and analyze. However, it was indisputable that some unmeasured confounders such as gout, uremia, and other uric acid metabolic disorder might still have affected the results. In addition, as a retrospective database study, it was difficult to account for the potential effect of therapy before ICU admission on serum uric acid levels, because such information was usually not documented. Thus, further well-designed prospective study is needed to confirm our results. Second, the present study included data from only one ICU center, which might limit the external applicability of the study results. Third, we found no association between serum uric acid on admission and long-term outcomes of critically ill patients, but whether the changes of serum uric acid would be associated with the clinical outcomes of the patients remained unknown.

Conclusion
==========

This large retrospective cohort study found that there was no statistically significant association of admission serum uric acid with 90-day mortality of ICU patients, providing a stronger confirmation of the controversial issue. However, further prospective basic and clinical research studies are still needed especially to reveal the underlined mechanisms and to evaluate the potential predictive value of changes of uric acid.
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Distribution of propensity scores.
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Kaplan--Meier survival curve of 28-day mortality.

**Abbreviations:** ICU, intensive care unit; PSM, propensity score matching.

###### 

Univariate Cox regression analysis of all patients on 90-day mortality

  Variables                                HR     95% CI       *p*-value
  ---------------------------------------- ------ ------------ --------------
  Age (years)                              1.02   1.02--1.03   \<**0.0001**
  Gender                                                       
   Male                                    1.0                 
   Female                                  1.07   0.91--1.26   0.4272
  SAPS II                                  1.04   1.03--1.04   \<**0.0001**
  Sepsis (based on ICD-9 codes)                                
   No                                      1.0                 
   Yes                                     2.02   1.63--2.49   \<**0.0001**
  Mechanical ventilation on first day                          
   No                                      1.0                 
   Yes                                     0.99   0.84--1.16   0.8727
  Renal replacement therapy on first day                       
   No                                      1.0                 
   Yes                                     1.22   0.89--1.67   0.2207
  Uric acid (mg/dL)                        1.02   1.00--1.05   0.0552
  Elixhauser Comorbidity Index (SID30)     1.04   1.03--1.04   \<**0.0001**
  Comorbidities                                                
   Congestive heart failure                                    
    No                                     1.0                 
    Yes                                    1.67   1.40--2.01   \<**0.0001**
   Cardiac arrhythmias                                         
    No                                     1.0                 
    Yes                                    1.60   1.33--1.92   \<**0.0001**
   Valvular disease                                            
    No                                     1.0                 
    Yes                                    1.53   1.12--2.10   **0.0078**
   Pulmonary circulation disorder                              
    No                                     1.0                 
    Yes                                    1.41   1.02--1.95   **0.0357**
   Peripheral vascular disorder                                
    No                                     1.0                 
    Yes                                    1.10   0.83--1.45   0.5042
   Hypertension                                                
    No                                     1.0                 
    Yes                                    1.08   0.84--1.38   0.5602
   Paralysis                                                   
    No                                     1.0                 
    Yes                                    1.08   0.65--1.81   0.7581
   Other neurological disease                                  
    No                                     1.0                 
    Yes                                    1.12   0.85--1.48   0.4238
   Chronic pulmonary disease                                   
    No                                     1.0                 
    Yes                                    1.01   0.81--1.27   0.9319
   Uncomplicated diabetes                                      
    No                                     1.0                 
    Yes                                    0.97   0.78--1.20   0.7806
   Complicated diabetes                                        
    No                                     1.0                 
    Yes                                    1.01   0.73--1.41   0.9442
   Hypothyroidism                                              
    No                                     1.0                 
    Yes                                    0.93   0.68--1.27   0.6455
   Renal failure                                               
    No                                     1.0                 
    Yes                                    1.11   0.89--1.39   0.3518
   Liver disease                                               
    No                                     1.0                 
    Yes                                    1.38   1.04--1.82   0.0246
   Peptic ulcer                                                
    No                                     1.0                 
    Yes                                    0.00   0.00--Inf    0.9866
   AIDS                                                        
    No                                     1.0                 
    Yes                                    1.19   0.49--2.88   0.6938
   Lymphoma                                                    
    No                                     1.0                 
    Yes                                    1.47   1.04--2.08   **0.0294**
   Metastatic cancer                                           
    No                                     1.0                 
    Yes                                    2.63   2.04--3.39   \<**0.0001**
   Solid tumor                                                 
    No                                     1.0                 
    Yes                                    0.99   0.61--1.64   0.9836
   Rheumatoid arthritis                                        
    No                                     1.0                 
    Yes                                    1.44   0.90--2.30   0.1302
   Coagulopathy                                                
    No                                     1.0                 
    Yes                                    1.71   1.43--2.06   \<**0.0001**
   Obesity                                                     
    No                                     1.0                 
    Yes                                    1.04   0.68--1.57   0.8648
   Weight loss                                                 
    No                                     1.0                 
    Yes                                    1.42   1.06--1.92   **0.0205**
   Fluid and electrolyte disorders                             
    No                                     1.0                 
    Yes                                    1.47   1.25--1.73   \<**0.0001**
   Blood loss anemia                                           
    No                                     1.0                 
    Yes                                    0.31   0.15--0.65   **0.0021**
   Deficiency anemia                                           
    No                                     1.0                 
    Yes                                    0.87   0.70--1.07   0.1879
   Alcohol abuse                                               
    No                                     1.0                 
    Yes                                    0.76   0.51--1.13   0.1709
   Drug abuse                                                  
    No                                     1.0                 
    Yes                                    0.41   0.20--0.87   **0.0198**
   Psychoses                                                   
    No                                     1.0                 
    Yes                                    0.45   0.24--0.88   **0.0188**
   Depression                                                  
    No                                     1.0                 
    Yes                                    0.81   0.55--1.20   0.2953

**Note:** Statistical significance (*p*\<0.05) is shown in bold.

**Abbreviations:** HR, hazard ratio; CI, confidence interval; SAPS II, Simplified Acute Physiology Score II; ICD-9, International Classification of Diseases-Ninth Revision; AIDS, acquired immune deficiency syndrome; SID, State Inpatient Database.
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Univariate Cox regression analysis of PSM cohort on 90-day mortality

                                           HR     95% CI       *p*-value
  ---------------------------------------- ------ ------------ -----------
  Age (years)                              1.00   0.99--1.00   0.5566
  Gender                                                       
   Male                                    1.0                 
   Female                                  0.95   0.80--1.13   0.5646
  SAPS II                                  1.01   1.00--1.01   0.0606
  Sepsis (based on ICD-9 codes)                                
   No                                      1.0                 
   Yes                                     1.16   0.93--1.43   0.1866
  Mechanical ventilation on first day                          
   No                                      1.0                 
   Yes                                     1.04   0.88--1.23   0.6044
  Renal replacement therapy on first day                       
   No                                      1.0                 
   Yes                                     0.98   0.71--1.34   0.8889
  Uric acid (mg/dL)                        1.01   0.98--1.03   0.6160
  Elixhauser Comorbidity Index (SID30)     1.00   0.99--1.00   0.3701
  Comorbidities                                                
   Congestive heart failure                                    
    No                                     1.0                 
    Yes                                    0.91   0.76--1.10   0.3262
   Cardiac arrhythmias                                         
    No                                     1.0                 
    Yes                                    0.99   0.82--1.19   0.9074
   Valvular disease                                            
    No                                     1.0                 
    Yes                                    1.05   0.77--1.44   0.7671
   Pulmonary circulation disorder                              
    No                                     1.0                 
    Yes                                    0.94   0.68--1.30   0.7088
   Peripheral vascular disorder                                
    No                                     1.0                 
    Yes                                    0.97   0.73--1.29   0.8432
   Hypertension                                                
    No                                     1.0                 
    Yes                                    0.93   0.72--1.19   0.5546
   Paralysis                                                   
    No                                     1.0                 
    Yes                                    0.88   0.52--1.50   0.6503
   Other neurological disease                                  
    No                                     1.0                 
    Yes                                    0.96   0.72--1.27   0.7778
   Chronic pulmonary disease                                   
    No                                     1.0                 
    Yes                                    0.97   0.77--1.21   0.7744
   Uncomplicated diabetes                                      
    No                                     1.0                 
    Yes                                    0.98   0.79--1.22   0.8543
   Complicated diabetes                                        
    No                                     1.0                 
    Yes                                    0.85   0.60--1.21   0.3748
   Hypothyroidism                                              
    No                                     1.0                 
    Yes                                    0.83   0.60--1.13   0.2361
   Renal failure                                               
    No                                     1.0                 
    Yes                                    0.90   0.71--1.13   0.3562
   Liver disease                                               
    No                                     1.0                 
    Yes                                    0.98   0.73--1.32   0.9022
   AIDS                                                        
    No                                     1.0                 
    Yes                                    0.72   0.30--1.73   0.4603
   Lymphoma                                                    
    No                                     1.0                 
    Yes                                    0.94   0.67--1.33   0.7409
   Metastatic cancer                                           
    No                                     1.0                 
    Yes                                    1.14   0.86--1.50   0.3634
   Solid tumor                                                 
    No                                     1.0                 
    Yes                                    0.89   0.54--1.46   0.6411
   Rheumatoid arthritis                                        
    No                                     1.0                 
    Yes                                    0.94   0.58--1.53   0.8061
   Coagulopathy                                                
    No                                     1.0                 
    Yes                                    0.99   0.82--1.20   0.9481
   Obesity                                                     
    No                                     1.0                 
    Yes                                    1.17   0.76--1.79   0.4717
   Weight loss                                                 
    No                                     1.0                 
    Yes                                    0.93   0.69--1.26   0.6577
   Fluid and electrolyte disorders                             
    No                                     1.0                 
    Yes                                    0.96   0.81--1.13   0.6048
   Blood loss anemia                                           
    No                                     1.0                 
    Yes                                    1.27   0.60--2.67   0.5344
   Deficiency anemia                                           
    No                                     1.0                 
    Yes                                    0.92   0.74--1.14   0.4309
   Alcohol abuse                                               
    No                                     1.0                 
    Yes                                    0.94   0.62--1.43   0.7775
   Drug abuse                                                  
    No                                     1.0                 
    Yes                                    1.21   0.57--2.55   0.6186
   Psychoses                                                   
    No                                     1.0                 
    Yes                                    0.93   0.48--1.79   0.8215
   Depression                                                  
    No                                     1.0                 
    Yes                                    0.94   0.63--1.41   0.7814

**Abbreviations:** PSM, propensity score matching; HR, hazard ratio; CI, confidence interval; SAPS II, Simplified Acute Physiology Score II; ICD-9, International Classification of Diseases-Ninth Revision; AIDS, acquired immune deficiency syndrome; SID, State Inpatient Database.
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![Flow chart of the study.\
**Abbreviations:** ICU, intensive care unit; LOS, length of stay.](tcrm-14-1347Fig1){#f1-tcrm-14-1347}

![Kaplan--Meier survival curve by different levels of uric acid of all patients and PSM cohort.\
**Abbreviations:** ICU, intensive care unit; PSM, propensity score matching.](tcrm-14-1347Fig2){#f2-tcrm-14-1347}

###### 

ROC curves of admission serum uric acid for prediction of clinical outcomes in all patients and the PSM cohort.

**Abbreviations:** ROC curves, receiver operating characteristic curves; ICU, intensive care unit; AUC, area under the ROC curves; PSM, propensity score matching.
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###### 

Characteristics and comparison between survivors and non-survivors of all patients

  Variable                                 All patients (n=2,123)   Survivors (n=1,545)    Non-survivors (n=578)   *p*-value
  ---------------------------------------- ------------------------ ---------------------- ----------------------- -------------
  Age (years)                              64.09 (51.39--75.74)     62.11 (48.68--73.83)   68.97 (57.79--79.52)    \<**0.001**
  Male                                     1,219 (57.42%)           895 (57.93%)           324 (56.06%)            0.437
  ICU mortality                            187 (8.81%)              0 (0.00%)              187 (32.35%)            \<**0.001**
  Hospital mortality                       379 (17.85%)             4 (0.26%)              375 (64.88%)            \<**0.001**
  Length of ICU stay (days)                3.79 (2.01--9.19)        3.47 (1.94--9.14)      4.21 (2.31--9.31)       **0.001**
  Length of hospital stay (days)           14.69 (8.05--26.37)      14.32 (7.90--26.00)    15.84 (9.03--27.50)     0.051
  Uric acid on admission (mg/dL)           5.40 (3.80--7.90)        5.30 (3.80--7.80)      5.70 (3.90--8.00)       0.119
  SAPS II on admission                     39 (30--49)              36.00 (28.00--45.00)   47.00 (39.00--56.00)    \<**0.001**
  Elixhauser Comorbidity Index (SID30)     11.00 (4.00--23.00)      11.00 (0.00--20.00)    17.00 (11.00--28.00)    \<**0.001**
  Sepsis (based on ICD-9 codes)            239 (11.26%)             132 (8.54%)            107 (18.51%)            \<**0.001**
  Mechanical ventilation on first day      1,032 (48.61%)           754 (48.80%)           278 (48.10%)            0.772
  Renal replacement therapy on first day   135 (6.36%)              93 (6.02%)             42 (7.27%)              0.295
  Comorbidities                                                                                                    
   Congestive heart failure                432 (20.35%)             268 (17.35%)           164 (28.37%)            \<**0.001**
   Cardiac arrhythmias                     426 (20.07%)             268 (17.35%)           158 (27.34%)            \<**0.001**
   Valvular disease                        109 (5.13%)              67 (4.34%)             42 (7.27%)              **0.006**
   Pulmonary circulation disorder          110 (5.18%)              70 (4.53%)             40 (6.92%)              **0.027**
   Peripheral vascular disorder            185 (8.71%)              130 (8.41%)            55 (9.52%)              0.423
   Hypertension                            239 (11.26%)             169 (10.94%)           70 (12.11%)             0.447
   Paralysis                               51 (2.40%)               36 (2.33%)             15 (2.60%)              0.723
   Other neurological disease              182 (8.57%)              127 (8.22%)            55 (9.52%)              0.343
   Chronic pulmonary disease               327 (15.40%)             238 (15.40%)           89 (15.40%)             0.997
   Uncomplicated diabetes                  365 (17.19%)             267 (17.28%)           98 (16.96%)             0.859
   Complicated diabetes                    133 (6.26%)              96 (6.21%)             37 (6.40%)              0.874
   Hypothyroidism                          170 (8.01%)              126 (8.16%)            44 (7.61%)              0.682
   Renal failure                           302 (14.23%)             212 (13.72%)           90 (15.57%)             0.278
   Liver disease                           152 (7.16%)              98 (6.34%)             54 (9.34%)              **0.017**
   Peptic ulcer                            1 (0.05%)                1 (0.06%)              0 (0.00%)               1.000
   AIDS                                    15 (0.71%)               10 (0.65%)             5 (0.87%)               0.569
   Lymphoma                                89 (4.19%)               55 (3.56%)             34 (5.88%)              **0.017**
   Metastatic cancer                       121 (5.70%)              54 (3.50%)             67 (11.59%)             \<**0.001**
   Solid tumor                             59 (2.78%)               43 (2.78%)             16 (2.77%)              0.985
   Rheumatoid arthritis                    49 (2.31%)               31 (2.01%)             18 (3.11%)              0.130
   Coagulopathy                            410 (19.31%)             252 (16.31%)           158 (27.34%)            \<**0.001**
   Obesity                                 84 (3.96%)               61 (3.95%)             23 (3.98%)              0.974
   Weight loss                             127 (5.98%)              80 (5.18%)             47 (8.13%)              **0.011**
   Fluid and electrolyte disorders         817 (38.48%)             548 (35.47%)           269 (46.54%)            \<**0.001**
   Blood loss anemia                       72 (3.39%)               65 (4.21%)             7 (1.21%)               \<**0.001**
   Deficiency anemia                       428 (20.16%)             322 (20.84%)           106 (18.34%)            0.201
   Alcohol abuse                           116 (5.46%)              91 (5.89%)             25 (4.33%)              0.158
   Drug abuse                              56 (2.64%)               49 (3.17%)             7 (1.21%)               **0.012**
   Psychoses                               68 (3.20%)               59 (3.82%)             9 (1.56%)               **0.008**
   Depression                              112 (5.28%)              86 (5.57%)             26 (4.50%)              0.327

**Notes:** Patients were grouped as survivors and non-survivors determined by 90-day mortality status. Data are expressed as median (interquartile range) or n (%) unless otherwise stated. Kruskal--Wallis and chi-square (or Fisher's exact) tests were used to analyse continuous and categorical variables, respectively. Statistical significance (*p*\<0.05) is shown in bold.

**Abbreviations:** ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score II; ICD-9, International Classification of Diseases, Ninth Revision; AIDS, acquired immune deficiency syndrome.

###### 

Characteristics and comparison between survivors and non-survivors of PSM cohort

  Variable                                 All patients (n=1,112)   Survivors (n=556)      Non-survivors (n=556)   *p*-value
  ---------------------------------------- ------------------------ ---------------------- ----------------------- -------------
  Age (years)                              69.00 (57.80--79.00)     69.13 (58.27--78.71)   68.97 (57.44--79.54)    0.920
  Male                                     621 (55.85%)             306 (55.04%)           315 (56.65%)            0.587
  ICU mortality                            176 (15.83%)             0 (0.00%)              176 (31.65%)            \<**0.001**
  Hospital mortality                       358 (32.19%)             3 (0.54%)              355 (63.85%)            \<**0.001**
  Length of ICU stay (days)                4.08 (2.16--9.48)        3.81 (2.08--9.42)      4.29 (2.39--9.49)       0.164
  Length of hospital stay (days)           15.98 (8.82--28.13)      16.18 (8.64--29.04)    15.87 (9.09--27.52)     0.687
  Uric acid on admission (mg/dL)           5.50 (3.80--8.20)        5.50 (3.70--8.30)      5.60 (3.90--7.90)       0.536
  SAPS II on admission                     46.00 (37.00--55.00)     45.00 (37.00--55.00)   46.00 (38.00--55.00)    0.202
  Elixhauser Comorbidity Index (SID30)     18.00 (10.00--28.00)     19.00 (9.75--28.00)    17.00 (10.75--27.25)    0.428
  Sepsis (based on ICD-9 codes)            184 (16.55%)             83 (14.93%)            101 (18.17%)            0.146
  Mechanical ventilation on first day      531 (47.75%)             263 (47.30%)           268 (48.20%)            0.764
  Renal replacement therapy on first day   86 (7.73%)               45 (8.09%)             41 (7.37%)              0.653
  Comorbidities                                                                                                    
   Congestive heart failure                321 (28.87%)             167 (30.04%)           154 (27.70%)            0.390
   Cardiac arrhythmias                     297 (26.71%)             148 (26.62%)           149 (26.80%)            0.946
   Valvular disease                        80 (7.19%)               38 (6.83%)             42 (7.55%)              0.642
   Pulmonary circulation disorder          80 (7.19%)               41 (7.37%)             39 (7.01%)              0.816
   Peripheral vascular disorder            105 (9.44%)              52 (9.35%)             53 (9.53%)              0.918
   Hypertension                            139 (12.50%)             71 (12.77%)            68 (12.23%)             0.786
   Paralysis                               30 (2.70%)               16 (2.88%)             14 (2.52%)              0.711
   Other neurological disease              106 (9.53%)              53 (9.53%)             53 (9.53%)              1.000
   Chronic pulmonary disease               183 (16.46%)             95 (17.09%)            88 (15.83%)             0.571
   Uncomplicated diabetes                  194 (17.45%)             97 (17.45%)            97 (17.45%)             1.000
   Complicated diabetes                    72 (6.47%)               39 (7.01%)             33 (5.94%)              0.465
   Hypothyroidism                          92 (8.27%)               51 (9.17%)             41 (7.37%)              0.276
   Renal failure                           182 (16.37%)             95 (17.09%)            87 (15.65%)             0.517
   Liver disease                           97 (8.72%)               48 (8.63%)             49 (8.81%)              0.915
   AIDS                                    12 (1.08%)               7 (1.26%)              5 (0.90%)               0.773
   Lymphoma                                68 (6.12%)               34 (6.12%)             34 (6.12%)              1.000
   Metastatic cancer                       99 (8.90%)               44 (7.91%)             55 (9.89%)              0.247
   Solid tumor                             35 (3.15%)               19 (3.42%)             16 (2.88%)              0.606
   Rheumatoid arthritis                    35 (3.15%)               18 (3.24%)             17 (3.06%)              0.864
   Coagulopathy                            292 (26.26%)             146 (26.26%)           146 (26.26%)            1.000
   Obesity                                 42 (3.78%)               20 (3.60%)             22 (3.96%)              0.753
   Weight loss                             93 (8.36%)               47 (8.45%)             46 (8.27%)              0.914
   Fluid and electrolyte disorders         509 (45.77%)             258 (46.40%)           251 (45.14%)            0.674
   Blood loss anemia                       11 (0.99%)               4 (0.72%)              7 (1.26%)               0.547
   Deficiency anemia                       218 (19.60%)             114 (20.50%)           104 (18.71%)            0.450
   Alcohol abuse                           48 (4.32%)               25 (4.50%)             23 (4.14%)              0.768
   Drug abuse                              12 (1.08%)               5 (0.90%)              7 (1.26%)               0.773
   Psychoses                               21 (1.89%)               12 (2.16%)             9 (1.62%)               0.509
   Depression                              51 (4.59%)               26 (4.68%)             25 (4.50%)              0.886

**Notes:** Patients were grouped as survivors and non-survivors determined by 90-day mortality status. Data are expressed as median (interquartile range) or n (%) unless otherwise stated. Kruskal--Wallis and chi-square (or Fisher's exact) tests were used to analyze continuous and categorical variables, respectively. Statistical significance (*p*\<0.05) is shown in bold.

**Abbreviations:** PSM, propensity score matching; ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score II; ICD-9, International Classification of Diseases, Ninth Revision; AIDS, acquired immune deficiency syndrome.

###### 

Association of uric acid with 90-day mortality, 28-day mortality, ICU mortality, and hospital mortality

  Subjects             HR/OR   95% CI       *p*-value
  -------------------- ------- ------------ ------------
  **All patients**                          
  90-day mortality                          
   Non-adjusted        1.02    1.00--1.05   0.0552
   Model I             1.00    0.98--1.03   0.7743
   Model II            1.01    0.98--1.03   0.5735
  28-day mortality                          
   Non-adjusted        1.03    1.00--1.06   0.0571
   Model I             1.01    0.98--1.04   0.6281
   Model II            1.01    0.98--1.04   0.5785
  ICU mortality                             
   Non-adjusted        1.03    0.99--1.08   0.1198
   Model I             1.01    0.96--1.05   0.8157
   Model II            1.00    0.96--1.05   0.9105
  Hospital mortality                        
   Non-adjusted        1.04    1.00--1.07   **0.0301**
   Model I             1.01    0.97--1.04   0.6263
   Model II            1.01    0.97--1.04   0.6924
  **PSM cohort**                            
  90-day mortality                          
   Non-adjusted        1.01    0.98--1.03   0.6160
   Model I             1.00    0.98--1.03   0.6835
  28-day mortality                          
   Non-adjusted        1.01    0.98--1.04   0.3784
   Model I             1.01    0.98--1.04   0.4894
  ICU mortality                             
   Non-adjusted        1.02    0.98--1.07   0.3709
   Model I             1.01    0.97--1.05   0.6934
  Hospital mortality                        
   Non-adjusted        1.02    0.98--1.05   0.3751
   Model I             1.01    0.97--1.04   0.6099

**Notes:** Association of uric acid with 90-day mortality and 28-day mortality was analyzed using Cox regression models, and associations of uric acid with ICU mortality and hospital mortality were analyzed using logistic regression models. For all patients, model I was adjusted for SAPS II, Elixhauser Comorbidity Index (SID30), and sepsis based on ICD-9 codes; model II was adjusted for SAPS II, sepsis based on ICD-9 codes, congestive heart failure, cardiac arrhythmias, valvular disease, pulmonary circulation disorder, liver disease, lymphoma, metastatic cancer, coagulopathy, weight loss, fluid and electrolyte disorders, blood loss anemia, drug abuse, and psychoses. For PSM cohort, model was adjusted for SAPS II. Statistical significance (*p*\<0.05) is shown in bold.

**Abbreviations:** ICU, intensive care unit; HR, hazard ratio; OR, odds ratio; CI, confidence interval; PSM, propensity score matching; SAPS II, Simplified Acute Physiology Score II; ICD-9, International Classification of Diseases, Ninth Revision.
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